Schizophrenia affects around 23 million people globally, or one in 345 people. The illness can beset sufferers with ...
A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance abuse, spends 10 weeks ...
As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
Researchers identify GRIN2A as a rare single-gene cause of early psychiatric disorders, with symptoms often beginning in ...
Few movies and TV shows accurately depict schizophrenia, and even fewer feature women with the condition—which undoubtedly plays a role in the misconception that schizophrenia only occurs in men. The ...
A major scientific review reveals a deep knowledge gap in how cognition is affected when schizophrenia and personality disorders occur together.
TipRanks on MSN
Neurocrine Biosciences advances schizophrenia treatment with new Phase 2a clinical study
Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has announced the initiation of a Phase ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. First, let me ...
TipRanks on MSN
Bristol-Myers Squibb to launch phase 3 trial for schizophrenia drug KarXT in adolescents
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results